A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who ...
A small clinical trial led by Dana-Farber Cancer Institute researchers has put a Salk Institute idea to the test in patients: ...
An investigational peptide receptor radionuclide therapy showed a manageable safety profile in patients. The therapy showed ...
Researchers added paricalcitol to chemotherapy and assessed outcomes in metastatic pancreatic cancer. The treatment remodeled ...
A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: ...
Preclinical studies at the Salk Institute laid the foundation for a question now being tested in patients: Can a vitamin ...
Nuclear medicine is reaching an inflection point as advances in imaging, theranostics and radiopharmaceuticals help ...
Androgen receptor (AR) signaling plays a critical role in prostate cancer progression and remains a primary therapeutic ...
Morning Overview on MSN
A new vitamin K-based compound just helped the brain regrow lost neurons in the lab — engineered straight at Alzheimer’s and Parkinson’s
Most drugs aimed at Alzheimer’s and Parkinson’s disease try to slow the damage. A small team at Japan’s Shibaura Institute of ...
A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that ...
Atom bomb’s unexpected souvenir, and the weight-loss drug that may be helping breast cancer patients
Scientists uncover a new crystal forged in the 1945 Trinity nuclear test while researchers link GLP-1 drugs to improved ...
Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results